Breast cancer heterogeneity and its implication in personalized precision therapy

被引：112

作者：

Guo, Liantao ^{[1
]}

Kong, Deguang ^{[1
]}

Liu, Jianhua ^{[1
]}

Zhan, Ling ^{[1
]}

Luo, Lan ^{[3
]}

Zheng, Weijie ^{[1
]}

Zheng, Qingyuan ^{[2
]}

Chen, Chuang ^{[1
]}

Sun, Shengrong ^{[1
]}

机构：

[1] Wuhan Univ, Dept Breast & Thyroid Surg, Renmin Hosp, 238 Jiefang Rd, Wuhan 430060, Hubei, Peoples R China

[2] Wuhan Univ, Dept Urol, Renmin Hosp, 238 Jiefang Rd, Wuhan 430060, Hubei, Peoples R China

[3] Guizhou Med Univ, Dept Breast Surg, Affiliated Hosp, 28 Guiyi Rd, Guiyang 550001, Guizhou, Peoples R China

来源：

EXPERIMENTAL HEMATOLOGY & ONCOLOGY | 2023年 / 12卷 / 01期

基金：

中国国家自然科学基金;

关键词：

Breast cancer; Heterogeneity; Cell interaction; Cell competition; Precision therapy; TUMOR-ASSOCIATED MACROPHAGES; ANTIBODY-DRUG CONJUGATE; EPITHELIAL-MESENCHYMAL TRANSITION; CELL-CELL INTERACTIONS; SINGLE-CELL; PROGESTERONE-RECEPTOR; ESTROGEN-RECEPTOR; GENE-EXPRESSION; MOLECULAR CHARACTERIZATION; ANTITUMOR-ACTIVITY;

D O I：

10.1186/s40164-022-00363-1

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Breast cancer heterogeneity determines cancer progression, treatment effects, and prognosis. However, the precise mechanism for this heterogeneity remains unknown owing to its complexity. Here, we summarize the origins of breast cancer heterogeneity and its influence on disease progression, recurrence, and therapeutic resistance. We review the possible mechanisms of heterogeneity and the research methods used to analyze it. We also highlight the importance of cell interactions for the origins of breast cancer heterogeneity, which can be further categorized into cooperative and competitive interactions. Finally, we provide new insights into precise individual treatments based on heterogeneity.

引用

页数：27

共 300 条

[1] Luminal B Breast Cancer: Molecular Characterization, Clinical Management, and Future Perspectives
Ades, Felipe
Zardavas, Dimitrios
Bozovic-Spasojevic, Ivana
Pugliano, Lina
Fumagalli, Debora
de Azambuja, Evandro
Viale, Giuseppe
Sotiriou, Christos
Piccart, Martine
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (25) : 2794 - +
[2] Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials
Albain, K.
Anderson, S.
Arriagada, R.
Barlow, W.
Bergh, J.
Bliss, J.
Buyse, M.
Cameron, D.
Carrasco, E.
Clarke, M.
Correa, C.
Coates, A.
Collins, R.
Costantino, J.
Cutter, D.
Cuzick, J.
Darby, S.
Davidson, N.
Davies, C.
Davies, K.
Delmestri, A.
Di Leo, A.
Dowsett, M.
Elphinstone, P.
Evans, V.
Ewertz, M.
Gelber, R.
Gettins, L.
Geyer, C.
Goldhirsch, A.
Godwin, J.
Gray, R.
Gregory, C.
Hayes, D.
Hill, C.
Ingle, J.
Jakesz, R.
James, S.
Kaufmann, M.
Kerr, A.
MacKinnon, E.
McGale, P.
McHugh, T.
Norton, L.
Ohashi, Y.
Paik, S.
Pan, H. C.
Perez, E.
Peto, R.
Piccart, M.
[J]. LANCET, 2012, 379 (9814) : 432 - 444
[3] Review of Microwaves Techniques for Breast Cancer Detection
Aldhaeebi, Maged A.
Alzoubi, Khawla
Almoneef, Thamer S.
Bamatraf, Saeed M.
Attia, Hussein
Ramahi, Omar M.
[J]. SENSORS, 2020, 20 (08)
[4] Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries
Allemani, Claudia
Matsuda, Tomohiro
Di Carlo, Veronica
Harewood, Rhea
Matz, Melissa
Niksic, Maja
Bonaventure, Audrey
Valkov, Mikhail
Johnson, Christopher J.
Esteve, Jacques
Ogunbiyi, Olufemi J.
Azevedo e Silva, Gulnar
Chen, Wan-Qing
Eser, Sultan
Engholm, Gerda
Stiller, Charles A.
Monnereau, Alain
Woods, Ryan R.
Visser, Otto
Lim, Gek Hsiang
Aitken, Joanne
Weir, Hannah K.
Coleman, Michel P.
[J]. LANCET, 2018, 391 (10125) : 1023 - 1075
[5] Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Alva, Ajjai S.
Mangat, Pam K.
Garrett-Mayer, Elizabeth
Halabi, Susan
Hansra, Damien
Calfa, Carmen J.
Khalil, Maged F.
Ahn, Eugene R.
Cannon, Timothy L.
Crilley, Pamela
Fisher, Julie G.
Haslem, Derrick S.
Shrestha, Sagun
Antonelli, Kaitlyn R.
Butler, Nicole L.
Warren, Sasha L.
Rygiel, Andrew L.
Ranasinghe, Shamika
Bruinooge, Suanna S.
Schilsky, Richard L.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (22) : 2443 - +
[6] The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging
Amin, Mahul B.
Greene, Frederick L.
Edge, Stephen B.
Compton, Carolyn C.
Gershenwald, Jeffrey E.
Brookland, Robert K.
Meyer, Laura
Gress, Donna M.
Byrd, David R.
Winchester, David P.
[J]. CA-A CANCER JOURNAL FOR CLINICIANS, 2017, 67 (02) : 93 - 99
[7] Prospective Study Evaluating the Impact of Tissue Confirmation of Metastatic Disease in Patients With Breast Cancer
Amir, Eitan
Miller, Naomi
Geddie, William
Freedman, Orit
Kassam, Farrah
Simmons, Christine
Oldfield, Maria
Dranitsaris, George
Tomlinson, George
Laupacis, Andreas
Tannock, Ian F.
Clemons, Mark
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (06) : 587 - 592
[8] Andersson A, 2021, NAT COMMUN, V12, DOI [10.1038/s41467-021-26271-2, 10.5281/ZENODO.3957256]
[9] Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2enegative advanced breast cancer: final overall survival results from SOLAR-1
Andre, F.
Ciruelos, E. M.
Juric, D.
Loibl, S.
Campone, M.
Mayer, I. A.
Rubovszky, G.
Yamashita, T.
Kaufman, B.
Lu, Y-S
Inoue, K.
Papai, Z.
Takahashi, M.
Ghaznawi, F.
Mills, D.
Kaper, M.
Miller, M.
Conte, P. F.
Iwata, H.
Rugo, H. S.
[J]. ANNALS OF ONCOLOGY, 2021, 32 (02) : 208 - 217
[10] Precision medicine for metastatic breast cancer-limitations and solutions
Arnedos, Monica
Vicier, Cecile
Loi, Sherene
Lefebvre, Celine
Michiels, Stefan
Bonnefoi, Herve
Andre, Fabrice
[J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2015, 12 (12) : 693 - 704

← 1 2 3 4 5 6 7 8 9 10 →